{{Drugbox
| IUPAC_name = 4-Methyl-5-(methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine
| image = 4,4'-Dimethylaminorex.svg
| drug_name = 4,4'-DMAR

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = Class A
| legal_DE = Anlage II
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Illegal in Czech Republic and Sweden

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1445569-01-6
| ATC_prefix = none
| PubChem = 20741615
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
|  ChemSpiderID = 19546433
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 18Y239214S

<!--Chemical data-->
| C=11 | H=14 | N=2 | O=1 
| molecular_weight = 190.24 g/mol
| smiles = CC(N=C(N)O1)C1C2=CC=C(C)C=C2
| StdInChI = 1S/C11H14N2O/c1-7-3-5-9(6-4-7)10-8(2)13-11(12)14-10/h3-6,8,10H,1-2H3,(H2,12,13)
| StdInChIKey = NPILLHMQNMXXTL-UHFFFAOYSA-N
}}

'''4,4'-Dimethylaminorex''' (abbreviated as '''4,4'-DMAR'''), sometimes referred to by the [[street name]] "Serotoni", is a [[psychostimulant]] and [[entactogen]] [[designer drug]] related to [[aminorex]], [[4-methylaminorex]] and [[pemoline]].<ref name="BrandtBaumann2014">{{cite journal|last1=Brandt|first1=Simon D.|last2=Baumann|first2=Michael H.|last3=Partilla|first3=John S.|last4=Kavanagh|first4=Pierce V.|last5=Power|first5=John D.|last6=Talbot|first6=Brian|last7=Twamley|first7=Brendan|last8=Mahony|first8=Olivia|last9=O'Brien|first9=John|last10=Elliott|first10=Simon P.|last11=Archer|first11=Roland P.|last12=Patrick|first12=Julian|last13=Singh|first13=Kuldip|last14=Dempster|first14=Nicola M.|last15=Cosbey|first15=Simon H.|url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1668/abstract|title=Characterization of a novel and potentially lethal designer drug(±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or ‘Serotoni’)|journal=Drug Testing and Analysis|volume=6|issue=7-8|year=2014|pages=684–695|issn=1942-7603|doi=10.1002/dta.1668}}</ref> It was first detected in the Netherlands in December 2012,<ref>[http://www.emcdda.europa.eu/attachements.cfm/att_190854_EN_TDAC12001ENC_.pdf EMCDDA 2012 Annual report on the state of the drugs problem in Europe]</ref> and has been sold as a [[designer drug]] around Europe since mid-2013.

4,4'-DMAR had been linked to at least 31 deaths in Hungary, Poland and the UK by February 2014, mostly when consumed in combination with other drugs.<ref>{{cite web | url=http://www.emcdda.europa.eu/system/files/publications/931/4%2C4'-DMAR%20Risk%20Assessment%20Report.pdf | title=Risk Assessment Report of a new psychoactive substance: 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-dimethylaminorex, 4,4′-DMAR) | publisher=European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) | date=November 2014}}</ref> Nineteen deaths linked to 4,4'-DMAR were reported in Northern Ireland in the same time period.<ref>[https://www.theguardian.com/society/2014/jun/05/unregulated-stimulant-drug-blamed-19-deaths-belfast-inquest Unregulated stimulant drug blamed for 19 deaths, Belfast inquest told. The Guardian, Thursday 5 June 2014]</ref>

4,4'-DMAR acts as a potent and balanced [[serotonin-norepinephrine-dopamine releasing agent]] (SNDRA), with [[EC50|EC<sub>50</sub>]] values for [[serotonin]], [[norepinephrine]], and [[dopamine]] [[neurotransmitter release|release]] of 18.5 nM, 26.9 nM, and 8.6 nM, respectively.<ref name="BrandtBaumann2014" />

==Legality==

The UK Home Office expressed intent to ban 4,4'-DMAR following advice from the [[Advisory Council on the Misuse of Drugs]]<ref>{{cite web | url=https://www.gov.uk/government/publications/letter-to-acmd-regarding-advice-on-mt-45-and-44-dmar | title=Letter to ACMD regarding advice on MT-45 and 4,4'-DMAR | publisher=UK Home Office | date=26 November 2014 | accessdate=19 February 2015}}</ref> and subsequently it became a class A drug on 11 March 2015.<ref>{{cite web | url=https://www.gov.uk/government/publications/circular-0032015-a-change-to-the-misuse-of-drugs-act-1971-control-of-mt-45-and-44-dmar | title=Circular 003/2015: a change to the Misuse of Drugs Act 1971: control of MT-45 and 4,4’-DMAR | publisher=UK Home Office | date=20 February 2015 | accessdate=11 March 2015}}</ref>

4,4'-DMAR is an [[Drugs controlled by the German Betäubungsmittelgesetz|Anlage II]] controlled substance in Germany as of May 2015.<ref>{{cite web | url=http://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html | title=Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel) | language=German | accessdate=29 June 2015}}</ref>

Sweden's public health agency suggested to classify 4,4'-DMAR as hazardous substance on November 10, 2014.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassade som hälsofarlig vara  | language=Swedish | accessdate=29 June 2015}}</ref>

4,4'-DMAR is also banned in the Czech Republic.<ref>{{cite web | url=http://www.mzcr.cz/Admin/_upload/files/3/Nov%C3%A9%20PL.pdf | title=Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení  vlády č. 463/2013 Sb.) | publisher=Ministerstvo zdravotnictví | language=Czech}}</ref>

==References==
{{Reflist|2}}

{{Entactogens|state=expanded}}
{{Stimulants}}

{{DEFAULTSORT:Dimethylaminorex, 4,4'-}}
[[Category:Entactogens and empathogens]]
[[Category:Stimulants]]
[[Category:Designer drugs]]
[[Category:Amines]]
[[Category:Serotonin-norepinephrine-dopamine releasing agents]]
[[Category:Oxazolines]]

{{nervous-system-drug-stub}}